143577-46-2

Basic information

• Product Name: R-1,1-dioxide-tetrahydro-3H-Pyrrolo[1,2-c][1,2,3]oxathiazole
• Synonyms: R-1,1-dioxide-tetrahydro-3H-Pyrrolo[1,2-c][1,2,3]oxathiazole;(R)-1,1-Dioxide-tetrahydro-3H-pyrrolo[1,2-c][1,2,3]oxathi azole,99%e.e.;(R)-Tetrahydro-3H-pyrrolo[1,2-c][1,2,3]oxathiazole 1,1-dioxide
• CAS NO: 143577-46-2
• Molecular Formula: C₅H₉NO₃S
• Molecular Weight: 163.19486
• Mol File: 143577-46-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 254.9±23.0 °C(Predicted)
• Appearance: /
• Density: 1.51±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -6.81±0.20(Predicted)
• CAS DataBase Reference: R-1,1-dioxide-tetrahydro-3H-Pyrrolo[1,2-c][1,2,3]oxathiazole(CAS DataBase Reference)
• NIST Chemistry Reference: R-1,1-dioxide-tetrahydro-3H-Pyrrolo[1,2-c][1,2,3]oxathiazole(143577-46-2)
• EPA Substance Registry System: R-1,1-dioxide-tetrahydro-3H-Pyrrolo[1,2-c][1,2,3]oxathiazole(143577-46-2)

Safety Data

• Hazardous Substances Data: 143577-46-2(Hazardous Substances Data)

Upstream product

• 68832-13-3 D-prolinol 

Downstream Products

• 1008108-76-6 C₁₈H₁₈N₃O₅S₂^(1-)*Li⁽¹⁺⁾ 
• 134454-21-0 (R)-2-(3,4-dimethoxybenzyl)-pyrrolidine 
• 144889-06-5 Lithium; (R)-2-benzyl-pyrrolidine-1-sulfonate 
• 144889-08-7 (R)-2-benzylpyrrolidine hydrochloride 
• 143577-47-3 Lithium; (R)-2-(3,4-dimethoxy-benzyl)-pyrrolidine-1-sulfonate 

Relevant articles and documents

Discovery of N-Substituted 3-Amino-4-(3-boronopropyl)pyrrolidine-3-carboxylic Acids as Highly Potent Third-Generation Inhibitors of Human Arginase i and II

Recent efforts to identify new highly potent arginase inhibitors have resulted in the discovery of a novel family of (3R,4S)-3-amino-4-(3-boronopropyl)pyrrolidine-3-carboxylic acid analogues with up to a 1000-fold increase in potency relative to the current standards, 2-amino-6-boronohexanoic acid (ABH) and N-hydroxy-nor-l-arginine (nor-NOHA). The lead candidate, with an N-2-amino-3-phenylpropyl substituent (NED-3238), example 43, inhibits arginase I and II with IC50 values of 1.3 and 8.1 nM, respectively. Herein, we report the design, synthesis, and structure-activity relationships for this novel series of inhibitors, along with X-ray crystallographic data for selected examples bound to human arginase II.

Process for preparing cyclic amines and intermediate products thereof

A process for preparing a cyclic amine of Formula I STR1 in which R1 is phenyl, optionally substituted by 1 to 3 lower alkoxy groups; R2, R3 and R4 are independently hydrogen or lower alkyl; and n is 1 or 2, comprises (1) converting an aminoalcohol of Formula III STR2 to a dioxooxathiazolidine of Formula II STR3 in which R2, R3, R4 and n are as defined above; and (2) reacting the dioxooxathiazolidine of Formula II with an organometallic nucleophile, R1 M*, wherein R1 is as defined above, and hydrolyzing the resulting sulfamate salt.